In a strategic move beyond liver-focused therapies, Intellia Therapeutics and Regeneron Pharmaceuticals have announced the expansion of their CRISPR collaboration. Following their 2016 partnership, the two companies achieved a milestone in 2021 with first-in-human gene editing results.
This expanded collaboration aims to develop in vivo CRISPR-based therapies for neurological and muscular diseases. Regeneron will contribute its proprietary adeno-associated virus vectors, while Intellia will bring its Nme2 CRISPR/Cas9 systems adapted for viral vector delivery.
Unlike traditional partnerships, no upfront payments are involved. Instead, the companies will focus on two in vivo non-liver targets initially. Intellia will lead the editing methodology, and Regeneron will handle targeted viral vector delivery.
Each company will independently lead development and commercialization for one target, with an option for the other to join in a 50/50 co-development and co-commercialization agreement. The collaboration, which began in 2016, has undergone revisions, with the latest extension until April 2024.
Their groundbreaking achievement so far includes the in vivo CRISPR/Cas9 genome editing candidate NTLA-2001 for transthyretin amyloidosis, demonstrating a reduction of serum levels of transthyretin, a key biomarkers for the disease. As Intellia and Regeneron pioneer CRISPR-based therapies beyond the liver, the scientific community anticipates potential breakthroughs in treating neurological and muscular diseases.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha™ 293 cell AAV high-yield platform and the π-Omega™ plasmid high-yield platform. PackGene’s mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Related News
Nanoscope Therapeutics Publishes Breakthrough Clinical Data Demonstrating Significant Vision Restoration in Retinitis Pigmentosa with Novel AAV-based MCO-010 Gene Therapy
Nanoscope Therapeutics has announced the publication of highly encouraging Phase 1/2a clinical trial data in the esteemed journal Molecular Therapy, showcasing significant vision restoration in patients suffering from retinitis pigmentosa (RP), a debilitating...
Capsida’s AAV CAP-004 Gene Therapy Shows Promise for Friedreich’s Ataxia in Primate Study at MDA Conference
Capsida Biotherapeutics' experimental gene therapy, CAP-004, for Friedreich's ataxia (FA), has demonstrated promising preclinical results in nonhuman primates. Research presented by Capsida at the 2025 MDA Clinical & Scientific Conference showed that a single...
FDA Grants Fast Track to Sanofi’s Chlamydia mRNA Vaccine
Sanofi is making significant strides in the fight against chlamydia, the most common sexually transmitted bacterial infection, for which there are currently no approved preventative vaccines. The French pharmaceutical group has recently been granted a fast-track...
Epicrispr Biotechnologies Announces $68M Series B to Advance First-in-Class FSHD Epigenetic Therapy to Clinic
Epicrispr Biotechnologies today announced the first close of its Series B financing, securing $68 million to support the clinical development of EPI-321, a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), a genetic...
Related Services
Plasmids GMP Services
Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE
AAV GMP Services
Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
Technology Platforms
PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE
